Menu
Search
|

Menu

Close
X

Cellectis SA CLLS.OQ (NASDAQ Stock Exchange Global Market)

32.65 USD
+0.29 (+0.90%)
As of Feb 16
chart
Previous Close 32.36
Open 31.80
Volume 47,116
3m Avg Volume 75,149
Today’s High 33.52
Today’s Low 31.80
52 Week High 35.07
52 Week Low 19.76
Shares Outstanding (mil) 35.42
Market Capitalization (mil) 1,013.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 6 analysts

KEY STATS

Revenue (mm, EUR)
FY17
33
FY16
62
FY15
66
EPS (EUR)
FY17
-2.609
FY16
-2.095
FY15
-0.972
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
20.98
5.77
Price to Book (MRQ)
vs sector
3.73
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.02
16.52
LT Debt to Equity (MRQ)
vs sector
0.01
12.22
Return on Investment (TTM)
vs sector
-27.62
14.43
Return on Equity (TTM)
vs sector
-27.69
16.13

EXECUTIVE LEADERSHIP

Andre Choulika
Chairman of the Board, Chief Executive Officer, Since 2000
Salary: €309,200.00
Bonus: €19,200.00
Thierry Moulin
Chief Financial Officer, Since 2014
Salary: --
Bonus: --
Mathieu Simon
Chief Operating Officer, Executive Vice President, Director, Since 2013
Salary: --
Bonus: --
David Sourdive
Executive Vice President-Corporate Development, Director, Since 2008
Salary: €214,400.00
Bonus: €34,400.00
Elsy Boglioli
Executive Vice President - Strategy and Corporate Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

8 rue de la Croix Jarry
PARIS     75013

Phone: +331.81691600

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

SPONSORED STORIES